港股早評:三大指數低開,內房股大跌,微盟集團開升超6%
隔夜美股三大指數收跌,熱門中概股多數上升。港股三大指數低開,恒指跌0.12%,國指跌0.19%,恒生科技指數跌0.16%。盤面上,連續上升的大型科技股多數走低,京東跌1.64%,阿里巴巴、網易、騰訊、百度、快手皆飄綠,美團、小米小幅上升;內房股大跌,萬科總裁祝九勝闢謠被帶走調查,但股價仍大跌超8%,融創中國、龍光集團、華潤置地等紛紛下跌;海運股、蘋果概念股、餐飲股多數下跌,中醫藥股繼續走低,中國中藥續跌1.56%創階段新低。另一方面,微信小店概念股繼續活躍,微盟集團升超6%,直播概念股、生物醫藥股、黃金股普遍上升,老鋪黃金升約3%有望挑戰新高。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.